Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 13/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rocepafant SCHEMBL29384155 | 1.00 | PTAFR (0.52) | PTAFRTBXAS1OPRK1PDE4DHPGD | |
| SCHEMBL9079980 | 0.92 | PTAFR (0.52) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 | |
| Setipafant SCHEMBL2110462 | 0.91 | PTAFR (0.55) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 | |
| Setipafant SCHEMBL29439897 | 0.91 | PTAFR (0.55) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 | |
| SCHEMBL9079664 | 0.90 | PTAFR (0.52) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 | |
| SCHEMBL9079821 | 0.90 | PTAFR (0.51) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 | |
| SCHEMBL9080699 | 0.89 | PTAFR (0.50) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 | |
| SCHEMBL9080175 | 0.86 | PTAFR (0.51) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 | |
| SCHEMBL9080734 | 0.86 | PTAFR (0.55) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 | |
| SCHEMBL9228304 | 0.86 | PTAFR (0.55) | PTAFRTBXAS1OPRK1PDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20080319198-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20080146812-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20030229078-A1 | Synthesis and use of thienotriazolodiazepines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-11 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030078517-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2003-04-24 | — | — | US | claimed |
| WO-2002079778-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| WO-2001083440-A2 | SYNTHESIS AND USE OF THIENOTRIAZOLODIAZEPINES | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2001-11-08 | — | — | WO | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| WO-1996007397-A2 | DELIVERY OF SOLID DRUG COMPOSITIONS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A. (US) | 1996-03-14 | — | — | WO | disclosed |
| US-5492906-A | ANTIASTHMATICS, ANTIALLERGENS, GASTROINTESTINAL PROTECTORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1996-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229078-A1 | Synthesis and use of thienotriazolodiazepines | TBXAS1, TBXA2R, P2RY10 | PTAFR 5/4885TBXAS1 1/4885OPRK1 1353/4885 |
| US-20080146812-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | PTAFR 3115/4885TBXAS1 1371/4885OPRK1 2500/4885 |
| US-20080319198-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | PTAFR 3115/4885TBXAS1 1371/4885OPRK1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.